On July 2, Innovent Biologics rose 4.27% in regular trading, trading at 82.9 HKD/share, with turnover of 322 million HKD. Multiple positive catalysts converged to drive the stock higher.

On June 30, Innovent Biologics signed a commercialization agreement with Eli Lilly for Verzenios (abemaciclib), a CDK4/6 inhibitor, in mainland China. Under the agreement, Innovent holds exclusive rights to import, market, distribute, and promote the drug domestically, strengthening its breast cancer pipeline. Eli Lilly retains responsibility for manufacturing, supply, and ongoing R&D.

Additionally, the company's core product mazdutide passed the preliminary review for inclusion in China's national medical insurance drug catalog on June 29, marking a critical step toward reimbursement coverage. A company spokesperson noted that only the diabetes indication is eligible for insurance consideration in China.

Within the Biotechnology sector, stocks broadly rallied. Among individual names, 3SBIO rose 11.66%, Akeso rose 8.4%, Remegen rose 6.86%, SKB Bio rose 5.59%, and BeiGene rose 2.05%, reflecting strong sector-wide momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)